ESC 2024: SELECT trial provides promising results for obesity-related HFpEF treatment

The SELECT trial at ESC Congress 2024 evaluated semaglutide for obesity-related HFpEF, showing reduced risk of MACEs in females with overweight/obesity and ASCVD, without diabetes, and significant reductions in body weight, waist circumference, and hsCRP with semaglutide compared to placebo, though ARR was higher in males. Semaglutide's efficacy was consistent by sex across cardiovascular, metabolic, and kidney endpoints, with comparable safety profiles between sexes.